NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. The cost-effectiveness ...
Find out why real estate is considered a good investment Barclay Palmer is a creative executive with 10+ years of creating or managing premium programming and brands/businesses across various ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback